DURECT (DRRX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

DURECT Revenue Highlights

Latest Revenue (Y)

$2.03M

Latest Revenue (Q)

$1.56M

Main Segment (Y)

Collaborative Research And Development And Other Revenue

Main Geography (Y)

Europe

DURECT Revenue by Period

DURECT Revenue by Year

Date	Revenue	Change
2024-12-31	$2.03M	-76.24%
2023-12-31	$8.55M	-55.67%
2022-12-31	$19.28M	37.96%
2021-12-31	$13.98M	-53.58%
2020-12-31	$30.11M	1.85%
2019-12-31	$29.56M	59.25%
2018-12-31	$18.56M	-62.25%
2017-12-31	$49.17M	250.59%
2016-12-31	$14.03M	-26.66%
2015-12-31	$19.12M	-1.43%
2014-12-31	$19.40M	26.59%
2013-12-31	$15.33M	-71.12%
2012-12-31	$53.07M	58.48%
2011-12-31	$33.49M	6.00%
2010-12-31	$31.59M	30.04%
2009-12-31	$24.29M	-6.41%
2008-12-31	$25.96M	-15.38%
2007-12-31	$30.68M	40.11%
2006-12-31	$21.89M	-23.37%
2005-12-31	$28.57M	106.24%
2004-12-31	$13.85M	17.05%
2003-12-31	$11.84M	64.72%
2002-12-31	$7.18M	10.13%
2001-12-31	$6.52M	106.78%
2000-12-31	$3.15M	3568.60%
1999-12-31	$86.00K	-

DURECT generated $2.03M in revenue during NA 2024, up -76.24% compared to the previous quarter, and up 6.87% compared to the same period a year ago.

DURECT Revenue by Quarter

Date	Revenue	Change
2024-09-30	$1.56M	-28.24%
2024-06-30	$2.17M	18.83%
2024-03-31	$1.83M	-31.55%
2023-12-31	$2.67M	53.04%
2023-09-30	$1.74M	-16.19%
2023-06-30	$2.08M	1.31%
2023-03-31	$2.05M	-38.04%
2022-12-31	$3.31M	-72.32%
2022-09-30	$11.98M	476.93%
2022-06-30	$2.08M	8.41%
2022-03-31	$1.92M	-73.76%
2021-12-31	$7.30M	237.04%
2021-09-30	$2.17M	-5.99%
2021-06-30	$2.30M	4.11%
2021-03-31	$2.21M	0.23%
2020-12-31	$2.21M	-17.74%
2020-09-30	$2.68M	-89.62%
2020-06-30	$25.84M	831.32%
2020-03-31	$2.77M	-74.03%
2019-12-31	$10.69M	-0.72%
2019-09-30	$10.76M	170.09%
2019-06-30	$3.98M	-3.53%
2019-03-31	$4.13M	13.90%
2018-12-31	$3.63M	-54.87%
2018-09-30	$8.04M	135.45%
2018-06-30	$3.41M	-2.15%
2018-03-31	$3.49M	-82.15%
2017-12-31	$19.54M	-5.82%
2017-09-30	$20.75M	380.34%
2017-06-30	$4.32M	-5.43%
2017-03-31	$4.57M	29.85%
2016-12-31	$3.52M	-6.04%
2016-09-30	$3.74M	18.56%
2016-06-30	$3.16M	-12.50%
2016-03-31	$3.61M	-30.17%
2015-12-31	$5.17M	8.94%
2015-09-30	$4.74M	6.80%
2015-06-30	$4.44M	-6.96%
2015-03-31	$4.77M	11.81%
2014-12-31	$4.27M	0.26%
2014-09-30	$4.26M	-7.05%
2014-06-30	$4.58M	-27.20%
2014-03-31	$6.29M	46.72%
2013-12-31	$4.29M	44.61%
2013-09-30	$2.97M	-24.30%
2013-06-30	$3.92M	-5.66%
2013-03-31	$4.15M	27.31%
2012-12-31	$3.26M	-14.79%
2012-09-30	$3.83M	-20.18%
2012-06-30	$4.80M	-88.35%
2012-03-31	$41.19M	360.94%
2011-12-31	$8.94M	10.10%
2011-09-30	$8.12M	3.60%
2011-06-30	$7.83M	-8.96%
2011-03-31	$8.60M	1.27%
2010-12-31	$8.50M	4.68%
2010-09-30	$8.12M	10.98%
2010-06-30	$7.31M	-4.60%
2010-03-31	$7.67M	57.15%
2009-12-31	$4.88M	-41.78%
2009-09-30	$8.38M	71.79%
2009-06-30	$4.88M	-20.83%
2009-03-31	$6.16M	-20.27%
2008-12-31	$7.73M	16.46%
2008-09-30	$6.63M	5.25%
2008-06-30	$6.30M	-2.10%
2008-03-31	$6.44M	-2.23%
2007-12-31	$6.58M	-

DURECT generated $1.56M in revenue during Q3 2024, up -28.24% compared to the previous quarter, and up 74.87% compared to the same period a year ago.

DURECT Revenue Breakdown

DURECT Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 20	Dec 19
Product	$135.00K	$6.27M	$6.08M	$6.17M	$11.44M
Collaborative Research And Development And Other Revenue	$1.90M	$2.28M	-	-	-

DURECT's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaborative Research And Development And Other Revenue (93.35%), and Product (6.65%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Collaborative Research And Development And Other Revenue	$425.00K	$369.00K	$606.00K	$496.00K	$1.13M	$508.00K	$643.00K	$1.52M	$10.59M	$606.00K	$495.00K	-	-	-	-	-	-	-	-	-
Product	-	$1.56M	$1.56M	$1.33M	$3.29M	$1.57M	$1.41M	$1.80M	$1.39M	$1.47M	$1.42M	$2.72M	$1.72M	$1.57M	$1.64M	$2.38M	$2.50M	$2.81M	$3.44M	$3.02M

DURECT's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Collaborative Research And Development And Other Revenue (100.00%).

DURECT Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Europe	$1.59M	$2.30M	$11.79M	$6.63M	$1.39M
Other Foreign Countries	$250.00K	$1.07M	$557.00K	$642.00K	$657.00K
United States	$189.00K	$4.62M	-	-	-
Japan	-	$559.00K	-	-	-
JAPAN	-	-	$1.49M	$1.01M	$1.17M
UNITED STATES	-	-	$5.45M	$5.69M	$26.89M

DURECT's latest annual revenue breakdown by geography, as of Dec 24: Europe (78.39%), Other Foreign Countries (12.31%), and United States (9.31%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
Other Foreign Countries	-	$135.00K	$205.00K	$164.00K	$684.00K	$213.00K	$175.00K	$127.00K	$162.00K	$153.00K	$115.00K	$164.00K	$123.00K	$172.00K	$183.00K	$-564.00K	$494.00K	$422.00K	$305.00K	$848.00K
Europe	-	$428.00K	$644.00K	$543.00K	$1.26M	$613.00K	$431.00K	$606.00K	$10.43M	$414.00K	$338.00K	$5.75M	$297.00K	$282.00K	$301.00K	$-865.00K	$498.00K	$668.00K	$1.08M	$1.03M
UNITED STATES	-	$1.21M	$1.18M	$973.00K	$1.14M	$1.28M	$1.60M	$1.25M	$1.40M	$1.21M	$1.32M	$1.68M	$1.25M	$-73.00K	$1.35M	$24.50M	$1.11M	$8.49M	-	-
JAPAN	-	$155.00K	$140.00K	$147.00K	$112.00K	$170.00K	$986.00K	$136.00K	$111.00K	$255.00K	$67.00K	$165.00K	$480.00K	$311.00K	$338.00K	$251.00K	$274.00K	$315.00K	-	-
J P	-	-	-	-	-	-	-	-	-	-	-	-	$303.00K	-	-	-	-	-	-	-
U S	-	-	-	-	-	-	-	-	-	-	-	-	$1.44M	-	-	-	-	-	-	-

DURECT Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
EVOK	Evoke Pharma	$10.25T	$2.65M
NBIX	Neurocrine Biosciences	$2.36B	$622.10M
ALKS	Alkermes	$1.56B	$378.14M
COLL	Collegium Pharmaceutical	$631.45M	$159.30M
ORGO	Organogenesis	$482.04M	$115.18M
IRWD	Ironwood Pharmaceuticals	$351.41M	$91.59M
AVDL	Avadel Pharmaceuticals	$169.12M	$50.02M
LFCR	Lifecore Biomedical	$128.26M	$35.15M
AQST	Aquestive Therapeutics	$57.56M	$13.54M
TKNO	Alpha Teknova	$37.74M	$9.58M
SNOA	Sonoma Pharmaceuticals	$12.73M	$3.56M
RDHL	RedHill Biopharma	$6.51M	$1.80M
DRRX	DURECT	$2.03M	$1.56M
SHPH	Shuttle Pharmaceuticals	-	-

DRRX Revenue FAQ

What is DURECT’s yearly revenue?

DURECT's yearly revenue for 2024 was $2.03M, representing a decrease of -76.24% compared to 2023. The company's yearly revenue for 2023 was $8.55M, representing a decrease of -55.67% compared to 2022. DRRX's yearly revenue for 2022 was $19.28M, representing an increase of 37.96% compared to 2021.

What is DURECT’s quarterly revenue?

DURECT's quarterly revenue for Q3 2024 was $1.56M, a -28.24% decrease from the previous quarter (Q2 2024), and a -10.67% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $2.17M, a 18.83% increase from the previous quarter (Q1 2024), and a 4.32% increase year-over-year (Q2 2023). DRRX's quarterly revenue for Q1 2024 was $1.83M, a -31.55% decrease from the previous quarter (Q4 2023), and a -11.05% decrease year-over-year (Q1 2023).

What is DURECT’s revenue growth rate?

DURECT's revenue growth rate for the last 3 years (2022-2024) was -89.47%, and for the last 5 years (2020-2024) was -93.25%.

What are DURECT’s revenue streams?

DURECT's revenue streams in c 24 are Product, and Collaborative Research And Development And Other Revenue. Product generated $135K in revenue, accounting 6.65% of the company's total revenue, down -97.85% year-over-year. Collaborative Research And Development And Other Revenue generated $1.9M in revenue, accounting 93.35% of the company's total revenue, down -16.73% year-over-year.

What is DURECT’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of DURECT was Collaborative Research And Development And Other Revenue. This segment made a revenue of $1.9M, representing 93.35% of the company's total revenue.